

Special Issue

Treatment of Cancer-Associated Thrombosis

Message from the Guest Editors

Venous thromboembolism (VTE) is a common and life-threatening complication in cancer patients. Cancer patients often suffer from multiple comorbidities and have both a greater risk of VTE recurrence and bleeding compared to noncancer patients. For many years, long-term therapy with low-molecular-weight heparin (LMWH) has been the standard of care for the management of cancer-associated thrombosis (CAT), but recent randomized controlled trials have indicated that direct oral anticoagulants (DOAC) are also effective. With the emergence of DOAC as a new option in the treatment of CAT, clinicians are now facing a multitude of choices for each individual patient. This Special Issue will cover the current clinical evidence supporting the standard of care and emerging treatment options for CAT. Data on adherence to CAT clinical practice guidelines and evidence on anticoagulant effects on the quality-of-life perception in cancer patients will be also welcomed.

Guest Editors

Dr. Corinne Frere

Prof. Dr. Dominique Farge

Dr. Jean M. Connors

Deadline for manuscript submissions

closed (30 June 2020)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/31068

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](http://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](http://mdpi.com/journal/cancers)

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

